TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With MDD Treated For 24 Weeks With Open-Label 50 mg DVS SR Formulation
Brief Summary: Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release Formulation (DVS SR)


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Arm Label: Supported Protocolized Discontinuation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD) | Arm Label: SPD + Mindfulness (MBCT); Type: EXPERIMENTAL; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD), Behavioral: Mindfulness Based Cognitive Therapy (MBCT) | Intervention Type: BEHAVIORAL; Name: Supported Protocolized Discontinuation (SPD); Assigned to Arm(s): SPD + Mindfulness (MBCT), Supported Protocolized Discontinuation | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy (MBCT); Assigned to Arm(s): SPD + Mindfulness (MBCT)
C: Arm Label: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg | Arm Label: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release Formulation 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release Formulation 25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Desvenlafaxine succinate sustained release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine succinate sustained release 50 mg, Drug: Desvenlafaxine succinate sustained release 25 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desvenlafaxine succinate sustained release 50 mg; Assigned to Arm(s): Desvenlafaxine succinate sustained release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine succinate sustained release 25 mg; Assigned to Arm(s): Desvenlafaxine succinate sustained release 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind).
Brief Summary: There is an unsatisfied medical need for a first-line treatment of proliferating IHs with a good benefit/risk profile. Based on the recent findings of encouraging results obtained with propranolol in a series of infants with severe Infantile Hemangioma (IH), propranolol is expected to be of significant benefit in the management of the condition. The present study has been designed to confirm efficacy of propranolol in severe IH by demonstrating superiority over placebo and to document the safety profile of propranolol in this indication.


Options:
A: Arm Label: Propranolol oral solution; Type: EXPERIMENTAL; Interventions: Drug: Propranolol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Propranolol; Assigned to Arm(s): Propranolol oral solution | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: propranolol for treatment of hemangiomas; Type: EXPERIMENTAL; Interventions: Drug: propranolol | Arm Label: Prednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Intervention Type: DRUG; Name: propranolol; Assigned to Arm(s): propranolol for treatment of hemangiomas | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Prednisolone
C: Intervention Type: DRUG; Name: Imiquimod 5% cream; Assigned to Arm(s): N/A
D: Arm Label: Cryocontact therapy; Type: EXPERIMENTAL; Interventions: Procedure: cryocontact therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Procedure: cryocontact therapy, Other: Control | Intervention Type: PROCEDURE; Name: cryocontact therapy; Assigned to Arm(s): Control, Cryocontact therapy | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Telemonitoring Versus Usual Care in a High Risk Elderly Population.
Brief Summary: Background: Older adults with multiple chronic illnesses are at risk for worsening functional and medical status with ensuing hospitalization. One goal of medical care is to prevent this decline. One method that may help slow this functional and medical decline is home telemonitoring.

Specific aim: To determine the effectiveness of home telemonitoring compared to usual care in reducing combined outcomes of hospitalization and emergency room visits in an at risk population over 60 years of age.

Materials and Methods: This will be a randomized trial of 200 patients into one of two interventions. Home telemonitoring involves the use of a computer device at home which records biometric and symptom data from patients. This information is monitored by mid level providers associated with the primary care medical practice. Usual care involves patients who make appointments with their providers as problems arise and utilize ongoing support like a 24 hours nurse line. The study participants are adults over 60 years of age within the highest 10% on elderly risk assessment (ERA) scores. Patients will have initial evaluations of gait, quality of life (SF12), Kokmen test of mental status, and PHQ 9. Patients will be followed for 1 year for primary outcomes of hospitalizations and emergency room visits. Secondary analysis will include quality of life, compliance with the device and attitudes about telemonitoring. Sample size is based upon an 80% power to detect a 36% difference between the groups. The primary analysis will involve Cox proportional time to event analysis comparing both interventions for telemonitoring or usual care. Secondary analysis will use T-test comparisons for continuous variables (quality of life, attitudes) and chi square for proportional analysis.


Options:
A: Arm Label: TREATMENT Group; Type: ACTIVE_COMPARATOR; Interventions: Device: HF Pressure Measurement System | Arm Label: CONTROL Group; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DEVICE; Name: HF Pressure Measurement System; Assigned to Arm(s): TREATMENT Group
B: Arm Label: Telemedicine; Type: OTHER; Interventions: Other: Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedicine
C: Arm Label: Home Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Intel Health Guide | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Intel Health Guide; Assigned to Arm(s): Home Telemonitoring | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitors and pharmacy management; Type: EXPERIMENTAL; Interventions: Other: Telemonitors and pharmacy management | Intervention Type: OTHER; Name: Telemonitors and pharmacy management; Assigned to Arm(s): Telemonitors and pharmacy management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physiologic Effects of High Flow Nasal Therapy in Patients With Acute Hypoxemic Respiratory Failure
Brief Summary: The aim of the study is to assess, in patients with acute hypoxemic respiratory failure, the short term physiologic effects of the high flow oxygen nasal therapy (Optiflow), in term of inspiratory muscle effort, gas exchange, comfort and dyspnea


Options:
A: Arm Label: Optiflow then CPAP; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Arm Label: CPAP then Optiflow; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Intervention Type: PROCEDURE; Name: O2stand; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: Optiflow; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP
B: Arm Label: Venturi mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Arm Label: Nasal high-flow; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal high-flow | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask | Intervention Type: DEVICE; Name: Nasal high-flow; Assigned to Arm(s): Nasal high-flow
C: Arm Label: HFNT; Type: EXPERIMENTAL; Interventions: Other: HFNT | Arm Label: NIV; Type: ACTIVE_COMPARATOR; Interventions: Other: NIV | Intervention Type: OTHER; Name: HFNT; Assigned to Arm(s): HFNT | Intervention Type: OTHER; Name: NIV; Assigned to Arm(s): NIV
D: Arm Label: Venturi group; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask, Drug: Oxygen | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: High Flow Nasal Canula (HFNC), Drug: Oxygen | Intervention Type: DEVICE; Name: High Flow Nasal Canula (HFNC); Assigned to Arm(s): HFNC group | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi group | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): HFNC group, Venturi group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physiologic Effects of High Flow Nasal Therapy in Patients With Acute Hypoxemic Respiratory Failure
Brief Summary: The aim of the study is to assess, in patients with acute hypoxemic respiratory failure, the short term physiologic effects of the high flow oxygen nasal therapy (Optiflow), in term of inspiratory muscle effort, gas exchange, comfort and dyspnea


Options:
A: Arm Label: Optiflow then CPAP; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Arm Label: CPAP then Optiflow; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Intervention Type: PROCEDURE; Name: O2stand; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: Optiflow; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP
B: Arm Label: HFNT; Type: EXPERIMENTAL; Interventions: Other: HFNT | Arm Label: NIV; Type: ACTIVE_COMPARATOR; Interventions: Other: NIV | Intervention Type: OTHER; Name: HFNT; Assigned to Arm(s): HFNT | Intervention Type: OTHER; Name: NIV; Assigned to Arm(s): NIV
C: Arm Label: Venturi group; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask, Drug: Oxygen | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: High Flow Nasal Canula (HFNC), Drug: Oxygen | Intervention Type: DEVICE; Name: High Flow Nasal Canula (HFNC); Assigned to Arm(s): HFNC group | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi group | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): HFNC group, Venturi group
D: Arm Label: Standard oxygen therapy; Type: EXPERIMENTAL; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Arm Label: nasal high flow oxygen therapy; Type: OTHER; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Intervention Type: DEVICE; Name: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand); Assigned to Arm(s): Standard oxygen therapy, nasal high flow oxygen therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of FOSTRAP Chewing Gum in Patients With Chronic Kidney Disease and Hyperphosphatemia.
Brief Summary: The phosphorus content in saliva is increased in chronic kidney disease. We hypothesize that a chewing gum that binds salivary phosphorus would be a novel, effective agent to reduce serum levels of phosphorus in patients with chronic kidney disease. We are testing this hypothesis using a chewing gum called FOSTRAP which has been shown to be effective in a small, non-randomized study in patients with chronic kidney disease on hemodialysis.


Options:
A: Arm Label: ASP1585 dose #1; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #2; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #3; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sevelamer hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer hydrochloride | Intervention Type: DRUG; Name: ASP1585; Assigned to Arm(s): ASP1585 dose #1, ASP1585 dose #2, ASP1585 dose #3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): Sevelamer hydrochloride
B: Arm Label: ESRD: FOSTRAP Chewing Gum; Type: ACTIVE_COMPARATOR; Interventions: Other: FOSTRAP Chewing Gum | Arm Label: CKD: FOSTRAP Chewing Gum; Type: ACTIVE_COMPARATOR; Interventions: Other: FOSTRAP Chewing Gum | Arm Label: ESRD Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo chewing gum | Arm Label: CKD Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo chewing gum | Intervention Type: OTHER; Name: FOSTRAP Chewing Gum; Assigned to Arm(s): ESRD: FOSTRAP Chewing Gum | Intervention Type: OTHER; Name: FOSTRAP Chewing Gum; Assigned to Arm(s): ESRD: FOSTRAP Chewing Gum | Intervention Type: OTHER; Name: FOSTRAP Chewing Gum; Assigned to Arm(s): CKD: FOSTRAP Chewing Gum | Intervention Type: OTHER; Name: FOSTRAP Chewing Gum; Assigned to Arm(s): ESRD: FOSTRAP Chewing Gum | Intervention Type: OTHER; Name: Placebo chewing gum; Assigned to Arm(s): CKD Matching Placebo, ESRD Matching Placebo
C: Arm Label: PhosLo; Type: EXPERIMENTAL; Interventions: Drug: calcium acetate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): PhosLo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Ferric Citrate; Type: EXPERIMENTAL; Interventions: Drug: Ferric Citrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ferric Citrate; Assigned to Arm(s): Ferric Citrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transcatheter Versus Surgical Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis
Brief Summary: A randomized clinical trial of transcatheter aortic valve implantation (TAVI) versus conventional surgical aortic valve replacement (SAVR) in patients older than 70 years of age suffering from severe aortic valve stenosis.

Study hypothesis: TAVI will reduce post-interventional morbidity and mortality compared to SAVR.


Options:
A: Arm Label: PIIA - SAPIEN XT; Type: EXPERIMENTAL; Interventions: Device: TAVR Implantation with SAPIEN XT | Arm Label: Control: SAVR; Type: ACTIVE_COMPARATOR; Interventions: Device: SAVR Implantation | Intervention Type: DEVICE; Name: TAVR Implantation with SAPIEN XT; Assigned to Arm(s): PIIA - SAPIEN XT | Intervention Type: DEVICE; Name: SAVR Implantation; Assigned to Arm(s): Control: SAVR
B: Arm Label: Medtronic CoreValve® System TAVI; Type: EXPERIMENTAL; Interventions: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Device: Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI) | Arm Label: SAVR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical Aortic Valve Replacement (SAVR) | Intervention Type: DEVICE; Name: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Assigned to Arm(s): Medtronic CoreValve® System TAVI | Intervention Type: PROCEDURE; Name: Surgical Aortic Valve Replacement (SAVR); Assigned to Arm(s): SAVR | Intervention Type: DEVICE; Name: Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI); Assigned to Arm(s): Medtronic CoreValve® System TAVI
C: Arm Label: Transcatheter Aortic Valve Implantation; Type: EXPERIMENTAL; Interventions: Procedure: Transcatheter Aortic Valve Implantation | Arm Label: Surgical Aortic Valve Replacement; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical Aortic Valve Replacement | Intervention Type: PROCEDURE; Name: Transcatheter Aortic Valve Implantation; Assigned to Arm(s): Transcatheter Aortic Valve Implantation | Intervention Type: PROCEDURE; Name: Surgical Aortic Valve Replacement; Assigned to Arm(s): Surgical Aortic Valve Replacement
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: CA-TAVR, Device: Amplatzer Duct Occluder | Intervention Type: PROCEDURE; Name: CA-TAVR; Assigned to Arm(s): A | Intervention Type: DEVICE; Name: Amplatzer Duct Occluder; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intensive Communication for Chronically Critically Ill
Brief Summary: This study was a trial of a formal system of family meetings to support family decision makers of chronically critically ill patients in the intensive care unit.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Facilitator-Based intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Facilitator-Based intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 2
B: Arm Label: Intensive Communication; Type: EXPERIMENTAL; Interventions: Other: Intensive Communication System | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intensive Communication System; Assigned to Arm(s): Intensive Communication
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: ICU-specific information program | Intervention Type: BEHAVIORAL; Name: ICU-specific information program; Assigned to Arm(s): Intervention group
D: Arm Label: Supportive Information Team Group; Type: EXPERIMENTAL; Interventions: Behavioral: Supportive Information Team Group | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supportive Information Team Group; Assigned to Arm(s): Supportive Information Team Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of a Fixed-dose Combination Polypill Medication (the Red Heart Pill) and Usual Care in Those at High Risk of Cardiovascular Disease.
Brief Summary: People with established cardiovascular disease need secondary prevention that addresses multiple risk factors. Complexity \& cost confer particularly difficult barriers to uptake of treatment; recovery from a stroke or heart attack typically necessitates multiple drugs for cholesterol, blood pressure and platelet function. A low-cost, fixed-dose, once-daily combination polypill, the Red Heart Pill, has been formulated by Dr Reddy's Laboratories. UMPIRE will evaluate whether provision of this polypill compared with usual medications improves adherence and clinical outcomes among high-risk patients in Europe and India. The results will be used to develop recommendations for equitable access.


Options:
A: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A
B: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2
D: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment

Answer: B